Clinical trial · Observational
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
NCT05224661CI-TRIAL-00113121MEASUREterminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study was stopped due to exhaustion of funding. No additional financial support could be obtained to continue study operations as planned.
Summary
Brief summary (as posted)
Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia in Remission | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prospective determination of the clinical utility of measurable residual disease (MRD) testing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Adult patients with AML in complete remission undergoing alloHCT
- description
- Adult patients with AML in complete remission undergoing alloHCT
- interventionNames
- Other: Prospective determination of the clinical utility of measurable residual disease (MRD) testing
Primary outcomes (2)
- measure
- Overall Survival
- timeFrame
- Through up to 3 years post-alloHCT
- description
- Overall survival post-alloHCT via comparison between those testing positive or negative using an optimized molecular monitoring approach.
- measure
- Cumulative incidence of relapse
- timeFrame
- Through up to 3 years post-alloHCT
- description
- Cumulative incidence of relapse post-alloHCT via comparison between those testing positive or negative using an optimized molecular monitoring approach.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Aged at least 18 years old at time of consent 4. Diagnosed with AML, in complete remission 1. Complete remission (CR) definition per local institutional criteria 2. CR with incomplete hematologic recovery (CRi) is not an exclusion criterion 3. MRD positivity is not an exclusion criterion 5. Undergoing alloHCT 6. Has a diagnostic AML specimen available Exclusion Criteria: 1. Diagnosis of acute promyelocytic leukemia 2. Prior alloHCT
References
Publications (0)
Data not yet available
No reference posted for this study.